[go: up one dir, main page]

SV2009002948A - Metodo para usar betahidroxi-beta-metilbutirato - Google Patents

Metodo para usar betahidroxi-beta-metilbutirato

Info

Publication number
SV2009002948A
SV2009002948A SV2008002948A SV2008002948A SV2009002948A SV 2009002948 A SV2009002948 A SV 2009002948A SV 2008002948 A SV2008002948 A SV 2008002948A SV 2008002948 A SV2008002948 A SV 2008002948A SV 2009002948 A SV2009002948 A SV 2009002948A
Authority
SV
El Salvador
Prior art keywords
type
cytokins
increase
methylbutirate
betahidroxi
Prior art date
Application number
SV2008002948A
Other languages
English (en)
Inventor
Debra L Thomas
Pradip Mukerji
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SV2009002948A publication Critical patent/SV2009002948A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pediatric Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

MÉTODOS PARA TRATAR UN INDIVIDUO CON UNA CONDICIÓN CARACTERIZADA POR UN DESEQUILIBRIO ENTRE LA PRODUCCIÓN DE CITOQUINAS DE TIPO (1) Y TIPO (2), DONDE EL MÉTODO COMPRENDE ADMINISTRAR AL INDIVIDUO UNA CANTIDAD DE (3-HIDROXI-F3-METILBUTIRATO (HMB) EFECTIVA PARA MODULAR O CAUSAR DE OTRA MANERA UN AUMENTO DE LA PROPORCIÓN ENTRE LAS CITOQUINAS DE TIPO (1) Y LAS DE TIPO (2), INCLUYENDO UN AUMENTO DE LA PROPORCIÓN ENTRE LAS CITOQUINAS DE TIPO (1) Y LAS DE TIPO (2) SIN EL CORRESPONDIENTE AUMENTO DE LOS NIVELES DE CITOQUINAS DE TIPO (2). TAMBIÉN SE REVELAN MÉTODOS PARA USAR HMB PARA TRATAR ASMA Y ALERGIAS. LOS MÉTODOS DE LA PRESENTE INVENCIÓN SE BASAN EN EL DESCUBRIMIENTO DE QUE EL HMB MODULA LA PRODUCCIÓN DE CITOQUINAS MÁS TÍPICAMENTE AUMENTANDO LAS CITOQUINAS DE TIPO (1) SIN UN CORRESPONDIENTE AUMENTO DE LAS CITOQUINAS DE TIPO (2)
SV2008002948A 2005-12-19 2008-06-19 Metodo para usar betahidroxi-beta-metilbutirato SV2009002948A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75225305P 2005-12-19 2005-12-19

Publications (1)

Publication Number Publication Date
SV2009002948A true SV2009002948A (es) 2009-02-19

Family

ID=38066532

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2008002948A SV2009002948A (es) 2005-12-19 2008-06-19 Metodo para usar betahidroxi-beta-metilbutirato

Country Status (17)

Country Link
US (4) US8778992B2 (es)
EP (2) EP1968564B1 (es)
JP (2) JP5227182B2 (es)
CN (2) CN101374509B (es)
AU (1) AU2006331950A1 (es)
BR (1) BRPI0620083A2 (es)
CA (1) CA2632262C (es)
CR (1) CR10085A (es)
EC (1) ECSP088539A (es)
ES (2) ES2548432T3 (es)
MY (1) MY180733A (es)
NZ (2) NZ568611A (es)
RU (2) RU2469719C2 (es)
SV (1) SV2009002948A (es)
TW (1) TWI424840B (es)
WO (1) WO2007075605A2 (es)
ZA (1) ZA200805297B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
AU2006331950A1 (en) 2005-12-19 2007-07-05 Abbott Laboratories Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance of type 1 and type 2 cytokine production
US9404924B2 (en) 2008-12-04 2016-08-02 Massachusetts Institute Of Technology Method of performing one-step, single cell RT-PCR
US9244080B2 (en) 2008-12-04 2016-01-26 Massachussetts Institute Of Technology Method for diagnosing allergic reactions
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
ES2689700T3 (es) 2008-12-09 2018-11-15 Metabolic Technologies, Inc. Intervención nutricional para mejorar la función y resistencia muscular
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9770424B2 (en) 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
ES2700777T3 (es) * 2009-07-03 2019-02-19 Nutreco Nederland Bv Pienso animal o comida para humanos para mejorar las propiedades de la barrera intestinal
AU2011210691A1 (en) 2010-01-29 2012-07-12 Abbott Laboratories Nutritional emulsions comprising calcium HMB
JP6076741B2 (ja) 2010-01-29 2017-02-08 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 無菌包装されているｈｍｂを含む栄養液
CN102762112A (zh) * 2010-01-29 2012-10-31 雅培制药有限公司 包含hmb的塑料包装的营养液
EP2442673B1 (en) * 2010-01-29 2013-07-10 Abbott Laboratories Nutritional powders comprising spray dried hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
AU2011210764A1 (en) * 2010-01-29 2012-07-05 Abbott Laboratories Nutritional emulsions comprising calcium HMB and soluble protein
TWI526161B (zh) * 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
JP6034309B2 (ja) * 2011-02-17 2016-11-30 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法
CN102524332A (zh) * 2011-12-19 2012-07-04 北京康比特体育科技股份有限公司 一种减肥压缩饼干及其制备方法
NZ630385A (en) * 2012-03-19 2016-04-29 Abbott Lab Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance
WO2013188258A1 (en) * 2012-06-11 2013-12-19 Abbott Laboratories Use of hmb to improve health outcomes for hospitalized patients
US20150238447A1 (en) * 2012-09-17 2015-08-27 Abbott Laboratories Beta-hydroxy-beta-methylbutryic acid-containing compositions and uses thereof
US20140272000A1 (en) * 2013-03-14 2014-09-18 Metabolic Technologies, Inc. Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same
JP2016513701A (ja) 2013-03-14 2016-05-16 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 長期身体不活動に関連するインスリン抵抗性の治療
CN105188417B (zh) * 2013-03-15 2017-08-08 雅培制药有限公司 包括β‑羟基‑β‑甲基丁酸钙、酪蛋白磷酸肽和蛋白质的营养组合物
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
EP3349745B1 (en) 2015-09-16 2023-12-13 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for enhancing recovery from soft tissue trauma
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
JP7156683B2 (ja) * 2018-09-28 2022-10-19 株式会社東洋新薬 経口組成物
MX2022016000A (es) * 2020-06-15 2023-06-15 Metabolic Tech Llc COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) Y AGENTES DE QUIMIOTERAPIA.

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3408210A (en) 1965-06-14 1968-10-29 Wilbert A. Heyman Dehydration of foods
US3542560A (en) 1967-12-06 1970-11-24 American Home Prod Infant formula with fat composition like human milk
GB1446965A (en) 1974-02-14 1976-08-18 Agricultural Vegetable Prod Preparation of food products
US4104290A (en) 1975-02-07 1978-08-01 H.L.S. Ltd., Industrial Engineering Company Process for separating oils and fats into liquid and solid fractions
US4311645A (en) 1980-03-24 1982-01-19 Hoffmann-La Roche Inc. Synthesis of SRS-active compounds
US4742081A (en) 1986-01-06 1988-05-03 Alfred Stracher Carnitine coupled pharmaceutical agents
US4866040A (en) 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
EP0367724B1 (en) 1988-10-31 1993-02-10 Sandoz Nutrition Ltd. Improvements in or relating to organic compounds
US5000975A (en) 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5457130A (en) 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
US5028440A (en) 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US5087472A (en) 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5167957A (en) 1990-09-06 1992-12-01 Virginia Tech Intellectual Properties, Inc. Compositions and methods for the treatment of dietary deficiencies
US5601860A (en) 1990-11-30 1997-02-11 American Home Products Corporation Corandomized fat compositions for infant formulas
FR2674102B1 (fr) 1991-03-18 1994-05-20 Meiji Seika Kaisha Ltd Aliment pour porcs et methode d'elevage des porcs utilisant cet aliment.
US5171442A (en) 1991-10-18 1992-12-15 Nakshbendi Ghassan F Water purification apparatus
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
DE69327468T2 (de) 1992-09-16 2000-05-11 Iowa State University Research Foundation, Inc. Verfahren zur reduktion der blutspiegel von gesamtcholesterin und ldl-cholesterin
US5447732A (en) 1992-11-25 1995-09-05 Ajinomoto Co., Inc. High-absorption mineral-containing composition and foods
US5348979A (en) 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
ES2105712T3 (es) 1993-05-13 1997-10-16 Loders Croklaan Bv Sustitutivos de grasa de leche humana a partir de mezclas interesterificadas de trigliceridos.
US6136858A (en) 1994-01-10 2000-10-24 Abbott Laboratories Infant formula and methods of improving infant stool patterns
US5780451A (en) 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
US5952314A (en) 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
US5444054A (en) 1994-04-01 1995-08-22 Abbott Labatories Method of treating ulcerative colitis
US5576287A (en) 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
US5726146A (en) 1994-12-06 1998-03-10 Natural Supplement Association, Incorporated Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass
KR0140248B1 (ko) 1995-03-23 1998-06-15 한상기 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법
DE19528461A1 (de) 1995-08-03 1997-02-06 Braun Melsungen Ag Präparat zur Ernährung
US5641531A (en) 1995-09-28 1997-06-24 Abbott Laboratories Nutritional liquid supplement beverage and method of making same
CA2252051C (en) 1996-04-11 2005-05-24 Loders Croklaan Bv Free flowing fat compositions
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US5756469A (en) 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US7504376B2 (en) 1996-08-12 2009-03-17 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
US6080788A (en) 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
DE29707308U1 (de) 1997-04-23 1997-06-26 Kunz, Armin, 66450 Bexbach Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
US6103764A (en) 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6475539B1 (en) 1998-05-07 2002-11-05 Abbott Laboratories Nutritionally complete low pH enteral formula
JP4175698B2 (ja) 1998-06-19 2008-11-05 サントリー株式会社 新規なトリグリセリド及びそれを含む組成物
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
DE69923322T2 (de) 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
US5976550A (en) 1998-11-20 1999-11-02 Engel; Peter H. Dietary food supplement
US20010008641A1 (en) 1998-11-25 2001-07-19 R. Douglas Krotzer Nutritionally active composition for bodybuilding
US6294206B1 (en) 1999-04-09 2001-09-25 Abbott Laboratories Powdered human milk fortifier
US6291525B1 (en) 1999-09-08 2001-09-18 Iowa State University Research Foundation, Inc. Method for improving a human's perception of his emotional state
AU784752B2 (en) 1999-10-18 2006-06-08 Northern Innovations Holding Corp. Food supplement for increasing lean mass and strength
GB9929919D0 (en) 1999-12-17 2000-02-09 Hannah Research Inst The Calcium phosphate nanoclusters and their applications
US6521591B1 (en) 2000-02-10 2003-02-18 N.V. Nutricia Pharmaceutical composition for muscular anabolism
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
WO2001077271A2 (en) 2000-04-06 2001-10-18 Conlinco, Inc. Conjugated linoleic acid compositions
JP4625156B2 (ja) 2000-04-10 2011-02-02 イーエヌ大塚製薬株式会社 癌化学療法に伴う副作用軽減剤
US6420342B1 (en) 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
US20050106219A1 (en) 2000-05-30 2005-05-19 Karlheinz Bortlik Primary composition comprising a lipophilic bioactive compound
BR0112913A (pt) 2000-08-03 2006-02-21 Univ North Carolina State aumento do desenvolvimento das espécies ovìparas por alimentação in ovo
ATE295690T1 (de) 2000-08-29 2005-06-15 Lonza Ag Verfahren zur herstellung einer granulierbaren mischung und carnitin-magnesium-hydroxycitrat
US20030203070A1 (en) 2000-09-26 2003-10-30 The Procter & Gamble Company Compositions containing sorbitan monoesters
EP1198991B1 (en) 2000-10-20 2012-12-19 Nutriz N.V: Non-dairy products derived from rice
NZ521894A (en) 2001-02-15 2006-08-31 Adeka Corp Products containing beta-glucan
JP3735070B2 (ja) 2001-03-26 2006-01-11 花王株式会社 容器詰乳化飲料
US6620427B2 (en) 2001-04-24 2003-09-16 Abbott Laboratories Method for improving bone mineralization
US20030021877A1 (en) 2001-06-13 2003-01-30 Cain Frederick William Micronised fat particles
DE10145818C1 (de) 2001-09-17 2002-10-10 Alfill Engineering Gmbh & Co K Sterilisiervorrichtung mit H202-Verdampfer
GB2381451A (en) 2001-11-01 2003-05-07 New Technology Res Ltd Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect
JP2003137790A (ja) 2001-11-01 2003-05-14 Mie Kariyou Kk β−２，１（β２→β１）結合連鎖フラクトースオリゴマーを含有するフラクトオリゴ糖を有効成分とする医薬
US7419596B2 (en) 2001-12-12 2008-09-02 Martek Biosciences Corporation Extraction and winterization of lipids from oilseed and microbial sources
DE10163676A1 (de) 2001-12-21 2003-07-10 Phenion Gmbh & Co Kg Verwendung von Hyperforin oder Extrakten aus Johanniskraut gegen anaphylaktische Schockzustände oder Osteoporose
US7168581B2 (en) 2001-12-21 2007-01-30 Rexam Medical Packaging Inc. Closure for a retort processed container having a peelable seal
DE60313769T2 (de) * 2002-04-23 2008-03-06 Aventis Pharmaceuticals Inc. 3-(pyridinyl-amino)-1h-indol-2-carbonsäure-verbindungen als inhibitoren der interleukin-4 genexpression
SE0201581D0 (sv) 2002-05-29 2002-05-29 Scandinavian Biotechnology Res New improved acyltransferase
WO2004002232A1 (en) 2002-06-28 2004-01-08 Theuer Richard C Fat compositions for infant formula and methods therefor
US20040048925A1 (en) 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US7445807B2 (en) 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
GB0301554D0 (en) * 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
US7332178B2 (en) 2003-04-25 2008-02-19 Abbott Laboratories Stable nutritional powder containing ascorbyl palmitate
FR2856596B1 (fr) 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
EP1689772A2 (en) 2003-10-14 2006-08-16 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease
IL158555A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Human breast milk lipid mimetic as dietary supplement
ES2314485T3 (es) 2003-12-24 2009-03-16 N.V. Nutricia Composiciones que comprenden acido pantotenico o derivados del mismo y su uso para estimular el apetito.
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20050249650A1 (en) 2004-05-07 2005-11-10 Fmc Technologies, Inc. Immersion retort
PT1799052E (pt) 2004-09-09 2011-01-20 Nestec Sa Métodos para o fabrico de produtos nutricionais com qualidade melhorada
US8557551B2 (en) 2004-09-10 2013-10-15 Dsm Ip Assets B.V. Compositions and methods for making and modifying oils
PL371081A1 (pl) 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
US8067052B2 (en) 2005-02-25 2011-11-29 Siddharth Shastri Nutritional composition and a container for the convenient transport and storage of the nutritional composition
CA2537452C (en) 2005-03-09 2013-12-24 Abbott Laboratories Concentrated human milk fortifier liquid
WO2006114791A1 (en) 2005-04-27 2006-11-02 Enzymotec Ltd. Human milk fat substitutes
BRPI0611245A2 (pt) 2005-06-06 2010-08-24 Bristol-Myers Squibb Company fàrmula infantil e seus usos
RU2385647C2 (ru) 2005-08-26 2010-04-10 Нестек С.А. Питание для пациентов, страдающих ожирением
MY147363A (en) 2005-09-20 2012-11-30 Nestec Sa Water dispersible composition and method for preparing same
US20090182050A1 (en) 2005-10-07 2009-07-16 Ocean Nutrition Canada, Ltd. Salts of Fatty Acids and Methods of Making and Using thereof
EP1973426A2 (en) 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions for preventing and reducing delayed onset muscle soreness
AU2006331950A1 (en) 2005-12-19 2007-07-05 Abbott Laboratories Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance of type 1 and type 2 cytokine production
RU2432090C2 (ru) 2006-01-31 2011-10-27 Нестек С.А. Питательная композиция
US20080119552A1 (en) 2006-11-17 2008-05-22 Novus International Inc. Matrix-embedded compositions having organic acids and fatty acids
US20080194407A1 (en) 2007-02-14 2008-08-14 Ashmead H Dewayne High nitrogen containing chelate compositions suitable for plant delivery
US20090110674A1 (en) 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
US8029830B2 (en) 2008-04-18 2011-10-04 Nuvocare Health Services Inc. Composition and method for promoting internal health and external appearance
EP2288268A1 (en) 2008-05-21 2011-03-02 Stokely-Van Camp, Inc. Milk-based recovery beverage
ES2689700T3 (es) 2008-12-09 2018-11-15 Metabolic Technologies, Inc. Intervención nutricional para mejorar la función y resistencia muscular
JP2009155336A (ja) 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤
US20090312419A1 (en) 2009-08-12 2009-12-17 Kneller Bruce W CREATINE -ßALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE
PL217815B1 (pl) 2009-12-14 2014-08-29 Olimp Lab Spółka Z Ograniczoną Odpowiedzialnością Napój izotoniczny z chelatami
CN101785566A (zh) 2010-01-22 2010-07-28 北京康比特体育科技股份有限公司 一种含有hmb的运动饮料
AU2011210691A1 (en) 2010-01-29 2012-07-12 Abbott Laboratories Nutritional emulsions comprising calcium HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
US10869843B2 (en) 2010-11-23 2020-12-22 Chemi Nutra Method for increasing muscle mass and strength
PH12013501385A1 (en) 2010-12-27 2013-09-02 Abbott Lab Methods for facilitating muscle recovery after a period of disuse betahydroxy-beta-methylbutyrate
WO2012097061A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
WO2013056048A2 (en) 2011-10-13 2013-04-18 Abbott Laboratories Nutritional products comprising beta-alanine
WO2013170189A1 (en) 2012-05-11 2013-11-14 Abbott Laboratories Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow
WO2013188258A1 (en) 2012-06-11 2013-12-19 Abbott Laboratories Use of hmb to improve health outcomes for hospitalized patients

Also Published As

Publication number Publication date
CN101374509A (zh) 2009-02-25
ES2548432T3 (es) 2015-10-16
US20120178811A1 (en) 2012-07-12
RU2469719C2 (ru) 2012-12-20
TWI424840B (zh) 2014-02-01
US20120177744A1 (en) 2012-07-12
CA2632262A1 (en) 2007-07-05
AU2006331950A1 (en) 2007-07-05
ZA200805297B (en) 2009-05-27
CA2632262C (en) 2015-04-07
TW200800151A (en) 2008-01-01
MY180733A (en) 2020-12-08
WO2007075605A2 (en) 2007-07-05
RU2008129605A (ru) 2010-01-27
EP2082738A8 (en) 2010-06-23
NZ593182A (en) 2012-09-28
US8796333B2 (en) 2014-08-05
JP2013136587A (ja) 2013-07-11
BRPI0620083A2 (pt) 2011-11-01
EP2082738B1 (en) 2015-09-16
JP5227182B2 (ja) 2013-07-03
ECSP088539A (es) 2008-07-30
CN101374509B (zh) 2013-06-19
US20070142469A1 (en) 2007-06-21
ES2548305T3 (es) 2015-10-15
NZ568611A (en) 2011-11-25
CR10085A (es) 2008-08-06
CN102225060A (zh) 2011-10-26
US20120189709A1 (en) 2012-07-26
WO2007075605A3 (en) 2008-06-26
EP1968564B1 (en) 2015-09-16
JP5696168B2 (ja) 2015-04-08
JP2009520029A (ja) 2009-05-21
EP2082738A1 (en) 2009-07-29
RU2011133891A (ru) 2013-02-20
EP1968564A2 (en) 2008-09-17
US8778992B2 (en) 2014-07-15

Similar Documents

Publication Publication Date Title
SV2009002948A (es) Metodo para usar betahidroxi-beta-metilbutirato
CL2008001761A1 (es) Polinucleotidos que codifican proteinas que modifican el desarrollo de la pared celular secundaria en plantas, casete de expresion y celula huesped que las comprenden, y metodo para modular l desarrollo e una planta completa o de la pared celular de la misma.
CL2020002841A1 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CO2020015153A2 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
GT200900264A (es) Moléculas y métodos para modular la pro-proteina
ECSP066421A (es) MODULACION DE LA EXPRESION DE eIF4E
DK1909890T3 (da) Organ til funktionel genskabelse af et beskadiget nervesystem
AR059772A1 (es) Composiciones que incuyen hemaglutinina metodos de elaboracion y metodos de uso de las mismas
MX2009012451A (es) Plantas con rasgos mejorados relacionados con el rendimiento y un metodo para producirlas.
NO20080462L (no) Krystallformer av astaxantin
AR054161A1 (es) Plantas con aumento del rendimiento y un metodo para prepararlas
MXPA05000122A (es) Compuestos utiles para la inhibicion de aldehido-deshidrogenasa.
AR035293A1 (es) Composicion oftalmica.
BR112016005652A8 (pt) aparelho de laser modular
UY28076A1 (es) Procedimiento para aumentar el rendimiento de las leguminosas.
AR055419A1 (es) Cultivar de arroz denominado cl 131
MX2023014444A (es) Modular la expresion de apolipoproteina (a).
AR053022A1 (es) Metodo para mejorar el desarrollo de plantas tolerantes o resistentes a los nematodos
ES2570933T3 (es) Aplicación de efectos a un camino de texto fusionado
BRPI0514572A (pt) ácidos de tiazolo-naftila
AR066530A1 (es) Metodos para producir una proteina beta-glucocerebrosidasa secretada
ATE393796T1 (de) Härtbare zusammensetzungen auf basis von epoxidharzen und 3(4)-(aminomethyl)-cyclohexan- propanamin und 1,4(5)-cyclooctandimethanamin
AR073057A1 (es) Combinaciones insecticidas de abamectina y ciflumetofeno y composiciones que las comprenden.
ATE480606T1 (de) Verwendung von knotenholzextrakten
MX2024015074A (es) Combinaciones de moduladores de rxfp1 e inhibidores de sglt2